JP4944799B2 - 緑膿菌（Ｐｓｅｕｄｏｍｏｎａｓａｅｒｕｇｉｎｏｓａ）ＩＡＴＳＯ１１血清型のリポ多糖類（ＬＰＳ）に対して特異的なヒトモノクローナル抗体 - Google Patents

緑膿菌（Ｐｓｅｕｄｏｍｏｎａｓａｅｒｕｇｉｎｏｓａ）ＩＡＴＳＯ１１血清型のリポ多糖類（ＬＰＳ）に対して特異的なヒトモノクローナル抗体 Download PDF

Info

Publication number
JP4944799B2
JP4944799B2 JP2007554515A JP2007554515A JP4944799B2 JP 4944799 B2 JP4944799 B2 JP 4944799B2 JP 2007554515 A JP2007554515 A JP 2007554515A JP 2007554515 A JP2007554515 A JP 2007554515A JP 4944799 B2 JP4944799 B2 JP 4944799B2
Authority
JP
Japan
Prior art keywords
monoclonal antibody
human monoclonal
human
antibody
pseudomonas aeruginosa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007554515A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008530988A (ja
JP2008530988A5 (OSRAM
Inventor
アロイス ベー． ラング
ミヒャエル ペー． ホルン
マルティン アー． インボデン
アドリアン ツエルヒャー
Original Assignee
ケンタ バイオテク アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ケンタ バイオテク アーゲー filed Critical ケンタ バイオテク アーゲー
Publication of JP2008530988A publication Critical patent/JP2008530988A/ja
Publication of JP2008530988A5 publication Critical patent/JP2008530988A5/ja
Application granted granted Critical
Publication of JP4944799B2 publication Critical patent/JP4944799B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2007554515A 2005-02-14 2006-02-13 緑膿菌（Ｐｓｅｕｄｏｍｏｎａｓａｅｒｕｇｉｎｏｓａ）ＩＡＴＳＯ１１血清型のリポ多糖類（ＬＰＳ）に対して特異的なヒトモノクローナル抗体 Expired - Fee Related JP4944799B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05003095A EP1690875A1 (en) 2005-02-14 2005-02-14 Human monoclonal antibody specific for lipopolysaccharides (LPS) of the pseudomonas aeruginosa IATS O11 serotype
EP05003095.6 2005-02-14
PCT/EP2006/001289 WO2006084758A1 (en) 2005-02-14 2006-02-13 Human monoclonal antibody specific for lipopolysaccharides (lps) of the pseudomonas aeruginosa iats o11 serotype

Publications (3)

Publication Number Publication Date
JP2008530988A JP2008530988A (ja) 2008-08-14
JP2008530988A5 JP2008530988A5 (OSRAM) 2011-10-13
JP4944799B2 true JP4944799B2 (ja) 2012-06-06

Family

ID=34933741

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007554515A Expired - Fee Related JP4944799B2 (ja) 2005-02-14 2006-02-13 緑膿菌（Ｐｓｅｕｄｏｍｏｎａｓａｅｒｕｇｉｎｏｓａ）ＩＡＴＳＯ１１血清型のリポ多糖類（ＬＰＳ）に対して特異的なヒトモノクローナル抗体

Country Status (11)

Country Link
US (1) US8197816B2 (OSRAM)
EP (2) EP1690875A1 (OSRAM)
JP (1) JP4944799B2 (OSRAM)
KR (2) KR20130018991A (OSRAM)
CN (1) CN101120018B (OSRAM)
AT (1) ATE480563T1 (OSRAM)
CA (1) CA2597701C (OSRAM)
DE (1) DE602006016736D1 (OSRAM)
ES (1) ES2348263T3 (OSRAM)
IL (1) IL184774A (OSRAM)
WO (1) WO2006084758A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090208535A1 (en) * 2004-06-28 2009-08-20 Proteome Systems Intellectual Property Pty Ltd Novel Methods of Diagnosis of Treatment of P. Aeruginosa Infection and Reagents Therefor
KR20120016086A (ko) * 2009-04-09 2012-02-22 켄타 바이오테크 아게 슈도모나스 애루지노사 혈청형 ｉａｔｓ ０１의 지질다당류(ｌｐｓ) 특이적 인간 단일클론 항체
US20130022603A1 (en) * 2010-02-18 2013-01-24 Symphogen A/S Antibody against serotype i lipopolysaccharide of pseudomonas aeruginosa
EP2361989A1 (en) * 2010-02-26 2011-08-31 Kenta Biotech AG Assays and kits for serotyping Pseudomonas aeruginosa and oligonucleotide sequences useful in such methods and kits
SG11201602490UA (en) * 2013-09-30 2016-04-28 Daiichi Sankyo Co Ltd Anti-lps o11 antibody
US11168131B2 (en) 2015-11-10 2021-11-09 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
ES2994374T3 (en) 2017-01-18 2025-01-23 Visterra Inc Antibody molecule-drug conjugates and uses thereof
EP4126064A1 (en) 2020-04-03 2023-02-08 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
EP4512826A3 (en) 2021-07-09 2025-04-02 Luxembourg Institute Of Health (LIH) Dimeric protein complexes and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ218499A (en) * 1985-12-10 1990-04-26 Genetic Systems Corp Monoclonal antibodies against pseudomonas aeruginosa, pharmaceutical compositions and detection methods
DE60130538T2 (de) 2000-02-03 2008-06-12 Millenium Pharmaceuticals, Inc., Cambridge Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
CA2422204A1 (en) * 2000-09-07 2002-03-14 John R. Schreiber Human antibodies against pseudomonas aeruginosa lps derived from transgenic mice

Also Published As

Publication number Publication date
EP1848741A1 (en) 2007-10-31
US20090068191A1 (en) 2009-03-12
KR20130018991A (ko) 2013-02-25
ES2348263T3 (es) 2010-12-02
CA2597701C (en) 2012-01-10
JP2008530988A (ja) 2008-08-14
IL184774A0 (en) 2007-12-03
US8197816B2 (en) 2012-06-12
CN101120018A (zh) 2008-02-06
ATE480563T1 (de) 2010-09-15
CN101120018B (zh) 2012-07-25
CA2597701A1 (en) 2006-08-17
KR20070107756A (ko) 2007-11-07
IL184774A (en) 2012-01-31
DE602006016736D1 (de) 2010-10-21
WO2006084758A1 (en) 2006-08-17
EP1848741B1 (en) 2010-09-08
EP1690875A1 (en) 2006-08-16

Similar Documents

Publication Publication Date Title
JP4691225B2 (ja) グラム陽性細菌のリポテイコ酸に特異的なオプソニン的かつ防御的モノクローナルおよびキメラ抗体
RU2529946C9 (ru) Моноклональное антитело человека против альфа-токсина из s. aureus и его применение в лечении или предотвращении образования абсцесса
JP2020506685A (ja) 抗体分子−薬物コンジュゲートおよびその使用
IL184774A (en) Human monoclonal antibody specific for lipopolysaccharides (lps) of the pseudomonas aeruginosa iats 011 serotype
KR20120128687A (ko) 녹농균의 혈청형 ｇ 지질다당류에 대한 항체
WO2021052461A1 (zh) 抗α-溶血素的抗体及其应用
EP1479695B1 (en) Human monoclonal antibody specific for lipopolysaccharides (LPS) of serotype IATS O6 of Pseudomonas aeruginosa
JP2012523221A (ja) 緑膿菌（Ｐｓｅｕｄｏｍｏｎａｓａｅｒｕｇｉｎｏｓａ）のＩＡＴＳＯ１血清型のリポ多糖類（ＬＰＳ）に対して特異的なヒトモノクローナル抗体
WO2006137938A2 (en) Antibody fragments for protection from pathogen infection and methods of use thereof
KR20230147616A (ko) 황색포도상구균 α-독소를 표적으로 하는 항원 결합단백질 및 이의 응용
CN114957460A (zh) 交叉中和金黄色葡萄球菌毒素的抗原结合蛋白及其用途

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110822

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110822

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120127

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120216

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120302

R150 Certificate of patent or registration of utility model

Ref document number: 4944799

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150309

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150309

Year of fee payment: 3

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150309

Year of fee payment: 3

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees